Oncview

John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.

Connie Batlevi, MD, PhD, explains the treatment options for relapsed/refractory follicular lymphoma and discusses a recent drug approval.

Javier L. Munoz, MD, MS, FACP, explains the treatment options for relapsed/refractory follicular lymphoma and provides insight into a recent clinical trial.

Recommendations for utilizing genomic testing to aid in treatment decisions for early-stage HR+ breast cancer based on updates to the NCCN guidelines.

Sameh Gaballa, MD, reviews the treatment options for relapsed/refractory follicular lymphoma and future treatment options.

Considerations for adding immunotherapy to the armamentarium for frontline treatment of extensive-stage small cell lung cancer.

The current role of genomic testing in HR+ breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.

Experts focus in on optimizing the use of minimal residual disease as a tool to guide decision making in the adjuvant setting for patients at risk for recurrence with colorectal cancer.

CancerNetwork spoke with Kenneth C. Anderson, MD, about treatment advances in myeloma - from smoldering, newly diagnosed, and relapsed/refractory multiple myeloma.

CancerNetwork spoke with Wade T. Iams, MD, about treatment options available and being evaluated in small cell lung cancer.